Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/47700, first published .
Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study

Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study

Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study

Journals

  1. Malhotra S, Cameron A, Gotham D, Burrone E, Gardner P, Loynachan C, Morin S, Scott C, Pérez-Casas C, Pai M. Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries. PLOS Global Public Health 2024;4(7):e0003418 View
  2. Mukherjee J, ul Hadi S, Chakrapani V, Rawat S, Srikrishnan A, Mahendra V, Baruah D, Mohapatra S, Gopinath U, Dange A, Rath P, Manchi P, Gangaramany A, Aggarwal P, Malhotra S, Keane M, Goyal R, Sagar M. Acceptability of broadly neutralizing antibodies (bNAbs) for HIV prevention among vulnerable populations in India: Findings from a qualitative study. PLOS One 2025;20(4):e0321725 View